WHITE PLAINS, N.Y.--(BUSINESS WIRE)--Orgenesis Inc. (ORGS) (“Orgenesis” or the “Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce its participation and sponsorship at the European Society of Gene & Cell Therapy (“ESGCT”) 20th Anniversary Congress, to be held October 26-29, 2012 in Versailles, France.
